515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)
Lim, J.S., Sundar, R., Wong, A., Yong, W-P., Soo, R., Chee, C.E., Lee, S.C., Goh, B.C., Dent, R., Jeraj, S. d/o Nathan, Kwok, L., Schiavon, G., Kaliaperumal, N., Foxley, A., Connolly, J.E., Tan, D.S.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
458MO Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic (met) cancers (Ca) (MEDIPAC)
Lim, J., Raghav, S., Wong, A., Yong, W.P., Soo, R.A., Chee, C.E., Lee, S.C., Goh, B-C., Dent, R.A., Chan, J.J., Wong, K.Y.K., d/o Nathan Jeraj, S., Kwok, L., Schiavon, G., Foxley, A., Tan, D.S.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article